Beyond the limits of life — ion technology that renews cellular time
Telom-X is a manufacturing-driven biotech built on Ion Cluster Control Technology (ICCT), which stabilizes natural minerals into ~1nm nano-ions. We connect cosmetics, functional food, ingredient supply, AI healthcare, and bioscience R&D on a single ion platform. Our flagship material, Telom-X-Gene, targets cellular reconstruction rather than symptom suppression.
Beyond the Limits of Life : Cellular Resurrection through Ion Technology
Ion Cluster Control Technology (ICCT)
We stabilize minerals extracted from natural sources into a sub-10nm — and ultimately ~1nm — mono-atomic state through high-pressure homogenization and AI-optimized processing. Because we control the ions’ electrical state rather than only reducing their size, delivery can proceed through the cell’s own ion channels without synthetic carriers.
Nano-ion stabilization
High-pressure homogenization and ultrasonic dispersion form ~1nm ion clusters and suppress re-aggregation.
Electrical stability
Ion clusters engineered toward a zeta-potential of ±45mV or higher to resist aggregation in vivo.
AI smart factory
Vision AI and process optimization across extraction, purification, mixing, filling, inspection, and control.
Two walls to clear
Absorption and electrical signalling — the two points ICCT is aimed at.
※ These diagrams illustrate the operating principle and are not plots of measured data.
Telom-X-Gene: beyond symptom relief, toward cellular reconstruction
Telom-X-Gene binds three ions — potassium (K⁺), sulfur (S²⁻), and chloride (Cl⁻) — into a stable cluster roughly 1nm in size. Without synthetic carriers, it is designed to travel the ion channels and nutrient-uptake pathways cells already use, with the research goal of returning a disturbed membrane potential to its normal range.
Four mechanisms, one healing environment
The mechanisms are not isolated. Delivery enables calming; a calmed state allows undisturbed physical rebuilding; and the rebuilt structure becomes the foundation for long-term cellular regeneration.
ICCT delivery
Sub-1nm stabilized nano-ions pass directly through skin mucosa and cell membranes, bypassing the sub-5% absorption ceiling that limits minerals above 50nm.
- BARRIERMinerals above 50nm are mostly deflected at the skin mucosa — under 5% absorption.
- ICCTStabilized into a sub-1nm monoatomic state, they pass straight through ion channels.
- RESULTDesigned to reach the dermal layer immediately on application.
Ion stabilization
Potassium and chloride ions re-balance the voltage inside and outside the cell, targeting the abnormal nerve transmission behind severe itching.
- VOLTAGEPotassium and chloride ions re-balance the voltage inside and outside the cell.
- BLOCKThe goal is to interrupt the abnormal nerve signalling behind severe itching.
- RELIEFA measurable drop in localized inflammatory markers was observed preclinically.
Sulfate reconstruction
Nano-sulfate ions act as a binding mortar between damaged epidermal cells, physically rebuilding barrier structure and water-retention capacity.
- BINDINGNano-sulfate ions act as high-strength mortar between damaged epidermal cells.
- RECOVERYCell division is promoted to replace tissue lost to scratching.
- MOISTUREThe water-retention architecture itself is rebuilt, not merely topped up.
Telomere regeneration
Lowering local oxidative stress and activating mitochondrial metabolism creates an environment that normalizes the regeneration cycle of aged and damaged cells.
- SHIELDNano-ions neutralize localized oxidative stress, limiting further inflammatory damage.
- ENERGYMitochondrial metabolism is stimulated directly, raising the skin’s own repair capacity.
- TELOMEREA cellular environment that slows telomere degradation normalizes the regeneration cycle.
One mechanism, two research directions
The same principle — normalizing membrane potential — leads to opposite outcomes depending on the target cell: regeneration in healthy tissue, apoptosis in abnormal cells.
Atopic dermatitis
Calms hyper-immunity and initiates sulfate-driven tissue repair. Rather than suppressing symptoms the way steroids do, the approach rebuilds the epidermal barrier itself.
Oncology pipeline
Along the very pathway tumor cells use to absorb blood glucose and other nutrients, ~1nm ions enter the cell, disrupting abnormal electrical signalling and inducing apoptosis — the mechanism now under study.
※ These figures were observed under specific conditions at the preclinical research stage and do not guarantee therapeutic effect in humans. Telom-X-Gene is a material under research and development and has not been approved as a drug for the diagnosis, treatment, or prevention of disease.
Why the approach differs
Conventional therapeutics and standard nanotech run into the same two walls — cytotoxicity and absorption below 5%. We redesigned the material to avoid both.
The old paradigm — suppression
Surface symptoms: topical itch and redness management
Chemical steroids and temporary emollients that suppress the response
24–48 hours of relief, followed by rebound inflammation and barrier collapse
The Telom-X-Gene paradigm — reconstruction
Root cause: cellular breakdown and membrane-potential imbalance
Nano-mineral structural repair and ion stabilization
Sustained barrier immunity and a normalized cell regeneration cycle
| Feature | Conventional therapeutics | Standard nanotech | Telom-X ICCT |
|---|---|---|---|
| Particle form & size | Macromolecules (hundreds of nm) | Aggregates (tens to hundreds of nm) | Monoatomic ions (≈1nm) |
| Cell permeability | Impermeable | Under 5% | Direct passage through ion channels |
| Cytotoxicity | High chemical side-effect burden | Toxicity from in vivo accumulation | Natural mineral-based · no toxicity observed |
| Manufacturing | Complex chemical synthesis | Physical milling (high variance) | AI-feedback autonomous control |
Swipe the table horizontally to see all columns.
※ This comparison is drawn from the Telom-X technical deck and is not an assessment of any specific competing product. “No toxicity observed” refers to in vivo oral toxicity testing at Seoul National University and other accredited testing under the stated conditions.
Four business areas
We pursue stable manufacturing revenue alongside the growth value of R&D.
Functional Cosmetics
Nano-ion cosmeceuticals across skincare, functional soaps, and scalp & hair care.
Functional Food
Premium ingredient supply and in-house health functional food development.
Ingredient Supply
Nano-ion concentrate platform for cosmetics, nutraceutical, and pharma partners.
Bioscience R&D
Oncology & cellular-regeneration pipeline and AI-based healthcare research (in development).
A cash-generating biotech model
Where drug-development biotechs burn cash for years and dilute heavily, Telom-X funds R&D from manufacturing and sales cash flow.
Direct brand sales
TELO-ION cosmeceuticals and HUDSON functional soaps generate early market revenue, funding R&D without dilution.
Global raw material platform
Supplying refined nano-ion components to international pharmaceutical and cosmetics manufacturers.
Monetizing the pipeline
High-value out-licensing (L/O) of the research pipeline and exclusive national distribution agreements.
Why a cash-generating structure
※ The curves illustrate the difference between two funding models; they are not any company’s actual results or a confirmed forecast.
AI Division — a smart-manufacturing partner
Alongside its bio-material business, Telom-X runs an AI division that carries out smart-factory transitions for small and mid-sized manufacturers. Built around TX-MES, its own production management system, the division covers everything from shop-floor data collection to ERP and PLC integration — and the manufacturing AI capability it accumulates goes straight into Telom-X’s own smart factory.
Production management for SMEs
Master data, transactions, inventory, planning, production, reporting, and monitoring in one in-house MES.
Smart-factory build-out
Process data collection, real-time monitoring, and ERP/PLC integration, delivered plant by plant.
AI on the shop floor
Vision inspection, automated document recognition, and data-driven process optimization applied to live production lines.
TELO-ION
A premium cosmeceutical brand carrying our nano-ion technology — built on naturally derived minerals and safety-tested manufacturing.
Skincare line
Nano-ion skincare focused on skin barrier and moisture balance.
Functional soap & cleansing
Functional soaps and cleansers continuing the Hudson heritage.
Special care
Focused care for sensitive skin (rolling launch).
※ Product labeling and claims are provided within the limits of applicable regulations.
Measure, recommend, and learn again
Material alone cannot tell you whether a user improved. Telom-X is building an affordable skin and scalp AI scanner and an ontology-based recommendation engine, creating a clinical feedback loop that records condition before and after use.
ScalpIQ scanner
A dedicated camera captures scalp and skin, syncing to the app in real time over Wi-Fi and Bluetooth — at a price point far below professional clinic equipment.
AI diagnostics & recommendation
Scores wrinkles, elasticity, moisture, pores, pigmentation, sebum, and sensitivity, while an ontology-based engine recommends personalized care and products.
Clinical data flywheel
Progress images captured by users accumulate into recovery-trajectory data that fuels B2B evidence, medical whitepapers, and the next round of product R&D.
The data comes back as product
Measurement is not a one-off. Progress records accumulate into clinical evidence, and that evidence becomes the starting point for the next product.
Visual tracking
Images captured by users are aligned with computer vision to record recovery trajectories.
App ecosystem
The ScalpIQ scanner and the AI skin diagnosis app share a single account.
Clinical data vault
Accumulated real-world usage is organized into a large-scale dataset.
Data flywheel
That dataset fuels B2B evidence and the R&D behind the next product.
※ ScalpIQ and the AI diagnostic application are in development; device and screen images represent design concepts. Analysis results are informational and do not replace medical diagnosis or judgement.
Manufacturing capability and intellectual property
Turning a lab result into consistent mass production — and securing that process as a right — is a barrier to entry as decisive as the material itself.
cGMP-grade smart factory (~1,000㎡)
Automating extraction, purification, mixing, filling, inspection, and control to scale lab-grade reproducibility to production volume.
Vision AI real-time inspection
Autonomous, real-time inspection of particle size and purity suppresses batch-to-batch variance.
Digital twin quality control
Mirroring the process as a virtual model removes human error and holds quality consistent across global batches.
Hybrid Patent 2.0
A portfolio covering both the monoatomic stabilization material and AI-feedback process control, targeting 100+ PCT international filings.
Hybrid Patent 2.0 — three layers of defence
A single material patent can be designed around. Telom-X builds material, process control, and international coverage as one package.
Core material
The ICCT monoatomic stabilization material itself sits at the centre of the claims.
Process control
Real-time optimization using Vision AI and digital-twin data is included in the scope.
Strategic coverage
Portfolios are built market by market, targeting 100+ PCT international filings.
Growth roadmap
From manufacturing revenue to a global ingredient platform, and onward to an R&D pipeline — an execution plan targeting a listing within seven years of our 2024 founding.
Birth · Market entry
Series A closing, smart-factory operation, and an aggressive TELO-ION B2C launch secure manufacturing-based revenue.
Expansion · Break-even
Global B2B ingredient supply and quasi-drug market entry prove platform value, targeting break-even (BEP) at roughly KRW 25 billion in revenue in year 3.
Ascent · Listing
Advancing the Telom-X-Gene pipeline and pursuing licensing-out (L/O), targeting roughly KRW 320 billion in revenue and a Nasdaq/KOSDAQ IPO in year 7.
※ These financial figures are business-plan targets, not confirmed results or a guarantee of future performance.
Evidence & trust
Grounded in accredited toxicity testing, particle analysis data, granted patents, and an FDA registration on record.
No. 71867-0002-1
※ An FDA registration (listing) indicates registration and differs from approval of therapeutic efficacy. Test results reflect the conditions of the tests performed; PCT filings and the smart factory include items in progress or planned.
Partnership · Investment · Technical documentation
Dedicated channels for global partners, investors, and ingredient customers.